The glucagon-like peptide 1 receptor agonist albiglutide is superior to placebo in preventing major adverse cardiovascular events in patients with type 2 diabetes mellitus. In the Harmony Outcomes trial, 9,436 patients with diabetes and cardiovascular disease were randomly assigned to a once-weekly subcutaneous injection of albiglutide (30–50 mg) or placebo, in addition to standard care. Over a median duration of 1.6 years, the rate of the primary end point (cardiovascular death, myocardial infarction or stroke) was 7.1% and 9.0% in the albiglutide and placebo groups, respectively (HR 0.78, 95% CI 0.68–0.90, P = 0.0006 for superiority). The rate of adverse events did not differ significantly between the groups.
References
Original article
Hernandez, A. F. et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet https://doi.org/10.1016/S0140-6736(18)32261-X (2018)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lim, G.B. Cardiovascular benefit of albiglutide. Nat Rev Cardiol 15, 728 (2018). https://doi.org/10.1038/s41569-018-0113-x
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41569-018-0113-x